Objectives: To characterize a novel subclass B1 metallo-b-lactamase (MBL) found in an MDR Pseudomonas aeruginosa clinical isolate.
Introduction
Carbapenem resistance in Gram-negative species of clinical importance is of utmost interest in healthcare systems worldwide. In general, carbapenem resistance can be caused by four mechanisms: (i) the loss of porins in the outer membrane; (ii) production of exporter pumps; (iii) mutations of PBPs; and (iv) the production of carbapenemases. [1] [2] [3] [4] [5] [6] While the most frequently detected carbapenemases in Enterobacteriaceae are of the KPC or OXA type, 7, 8 the situation is different within Pseudomonas aeruginosa, with acquired Ambler class B metallo-b-lactamases (MBLs) being the most common class of carbapenemases. 9, 10 The most prevalent MBLs in P. aeruginosa belong to the VIM or IMP type, but other types, like NDM, AIM, GIM, FIM and SPM, have also been reported sporadically or in single isolates. [10] [11] [12] In Germany, VIM, IMP and GIM are the most commonly found MBL families in P. aeruginosa.
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A subclass B1 MBL that has never been found in this species so far is KHM-1, which was identified in 1997 in an MDR Citrobacter freundii isolate from Japan. 14 Since then, no other appearance of this enzyme has been reported.
Here we describe the identification and characterization of a novel MBL, HMB-1, which was found in a clinical P. aeruginosa isolate from Germany.
Materials and methods
The study was performed at the German National Reference Laboratory for Multidrug-resistant Gram-negative Bacteria.
Bacterial isolate and phenotypic testing
The isolate P. aeruginosa NRZ-03096 was recovered in 2012 from an anal swab from a 70-year-old German female without any known travel history who was hospitalized for bone marrow transplantation in a university V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
hospital in Northern Germany. It showed high MICs of carbapenems and was referred to the German National Reference Laboratory for Multidrugresistant Gram-Negative Bacteria for further analysis. MICs of antibiotics were determined by broth microdilution in preconfigured microtitre plates (Merlin Diagnostika, Bornheim-Hersel, Germany). Detection of MBL production was performed by MBL Etest Imipenem (bioMérieux, Nürtingen, Germany), an EDTA combined disc test (EDTA-CDT) and an EDTA bioassay based on cell-free extracts. 15, 16 PCR assays and DNA sequencing Prior to any other investigation, PCRs were performed for genes encoding VIM, IMP, NDM, GIM, SIM, SPM, AIM, DIM and KHM using whole-cell DNA of the isolate as a template. PCR products and recombinant plasmids based on the pBK-CMV vector were Sanger sequenced. WGS and genome assembly were performed by MicroSynth (Balgach, Switzerland) on a PacBio RSII instrument.
DNA sequence analysis and MLST
Genome annotation was performed using the BASys-Server and manually revised. 17 The ST of the isolate was identified with the sequence definition tool of the P. aeruginosa MLST web site (http://pubmlst.org/paeruginosa/). Bacterial promoter structures were analysed using the online web tools PromoterHunter, BPROM and SCOPE. [18] [19] [20] Resistome analysis was performed using the CARD Database. 21 Cloning of bla Shotgun cloning experiments were performed using the pBK-CMV vector and HindIII, EcoRI, XhoI, BamHI and MboI as restriction enzymes. Selection of clones was performed on LB agar plates containing 100 mg/L ampicillin. The bla HMB-1 gene was amplified using primers HMB-1-BamHI-fw (AAA AGG ATC CAA TTT AAT CGC ACG AAT AG) and HMB-1-XhoI-rev (TTT TCT CGA GTT ATT TCT TCT TTG CAA CC) using whole-cell DNA of P. aeruginosa NRZ-03096 as a template. The gene was cloned into the pBK-CMV vector using BamHI and XhoI as restriction sites, yielding the recombinant plasmid pMB3014-HMB-1. The bla KHM-1 gene was commercially synthesized (Eurofins Genomics, Ebersberg, Germany) and also cloned into the pBK-CMV vector (pMB3037-KHM-1) to serve as a reference for MIC studies and determination of kinetic parameters. pMB3014-HMB-1 and pMB3037-KHM-1 were confirmed by Sanger sequencing and transformed into Escherichia coli TOP10 for production of HMB-1 and KHM-1.
Biochemical characterization of HMB-1 and KHM-1 HMB-1 and KHM-1 were purified by fast protein liquid chromatography (FPLC) as previously described. 22 Using this procedure, HMB-1 and KHM-1 were purified to near homogeneity with a purity of .96%, as estimated and quantified by SDS-PAGE (data not shown). Hydrolysis of b-lactam antibiotics was monitored by measuring the absorbance changes resulting from the opening of the b-lactam ring. The experiments were performed at 25 C in buffer H (50 mM HEPES/50 lM ZnSO 4 , pH 7.5) under the experimental conditions reported previously, using an Eppendorf BioSpectrometer (Eppendorf, Hamburg, Germany). [23] [24] [25] The k cat and K m kinetic parameters were determined by non-linear regression under initial rate conditions using the Michaelis-Menten equation and with three independent enzyme preparations.
Nucleotide sequence accession number
The nucleotide sequence of bla HMB-1 and Tn6345 has been submitted to GenBank and was assigned the accession number KU961660.
Results and discussion

Susceptibility testing and identification of HMB-1
According to EUCAST criteria, 26 the isolate P. aeruginosa NRZ-03096 was resistant to penicillins, cephalosporins and to meropenem and doripenem, while it was intermediate for imipenem, with an MIC of 8 mg/L (Table 1) . MBL production was indicated by the performance of the MBL Etest Imipenem, the EDTA-CDT and the EDTA bioassay (data not shown). Regarding non-b-lactams, the isolate was resistant to ciprofloxacin, levofloxacin, gentamicin, tobramycin and tigecycline, while it was susceptible to amikacin and colistin (data not shown).
As all PCRs for known MBLs were negative, shotgun cloning experiments were performed in order to identify the molecular basis of carbapenem resistance. Finally, experiments with MboI yielded a clone with increased resistance to carbapenems and the 4575 bp insert of the contained recombinant plasmid pMB3013 was sequenced. It harboured a 726 bp ORF that coded for a 241 amino acid protein that showed an identity of only 73.6% at the nucleotide level and 74.3% at the amino acid level to the MBL KHM-1 ( Figure 1 ). Despite the numerous amino acid substitutions, the predicted secondary structure and the conserved zinc-binding ligands of the novel MBL were identical to KHM-1 and other subclass B1 MBLs. 27 Initially, the novel enzyme was named KHM-2, but with respect to the significant differences between KHM-1 and the novel MBL, a new family name was chosen and the enzyme was renamed HMB-1 (for Hamburg MBL).
Genetic analysis of bla HMB-1
As the recombinant plasmid pMB3013 obtained from shotgun cloning exhibited little information on the genetic environment or the localization of bla HMB-1 , the isolate P. aeruginosa NRZ-03096 was subjected to WGS (PacBio). The complete genome of the isolate was assembled as one single circular contig with a size of 6.9 million bp, which was carrying the bla HMB-1 gene, showing a chromosomal localization of the gene. This was contrary to the next nearest relative bla KHM-1 , which was described as plasmid encoded in C. freundii.
14 Resistome analysis showed that P. aeruginosa NRZ-03096 carried additional resistance genes conferring resistance to aminoglycosides [aph(3 0 )-IIb, amrAB], fluoroquinolones (gyrA), b-lactams (bla PDC-8 , bla OXA-50 ), chloramphenicol (catB7), fosfomycin (fosA), triclosan (triABC) and bicyclomycin (bcr-1) and several genes coding for multidrug efflux complexes (emrE, mexAB, mexCD, mexEF, mexGHI, mexJK, mexPQ, mexVW). As the isolate was resistant to aminoglycosides and fluoroquinolones, this was consistent with the MIC data.
Analysis of the genetic context of bla HMB-1 revealed four transposase-encoding genes in the vicinity of the gene. bla HMB-1 was identified as part of a large transposon structure flanked by 14 bp direct repeats that was named Tn6345, consisting of an IS1595 transposase gene, the genes bla HMB-1 and aac(3)-like and a Tn3 family tnpA gene downstream of the aac(3)-like gene (Figure 2 ). The tnpA gene showed 97% homology to transposase genes identified in several Salmonella enterica plasmids from Turkey, but no further similarities to these plasmids were observed. 28 The IS1595 transposase gene was flanked by 24 bp inverted repeats, but the repeat regions did not encompass the HMB-1-encoding gene, speaking against an IS1595-mediated mobilization of bla HMB-1 . No association of bla HMBCharacterization of HMB-1 JAC 1 with the Tn3 family tnpA gene upstream of IS1595 was observed. Downstream of the bla HMB-1 gene, an ORF showing 68% homology to a gene annotated as aac(3) in the GenBank database (accession number BA000045.2) was identified. This ORF was part of the 4575 bp insert from pBM3013 obtained by shotgun cloning, and the clone E. coli TOP10-pMB3013 showed increased MICs of gentamicin and tobramycin compared with the control strain, indicating an aminoglycoside-modifying activity of the encoded protein (data not shown). Further downstream, a truncated tnpA gene also belonging to the Tn3 family was identified. Surprisingly, the genetic context of the bla HMB-1 gene did not contain any integron structures. This is remarkable, as subclass B1 MBL genes are usually part of conserved class 1 integrons. 8, 29 In silico promoter analysis of the genetic environment revealed that the putative promoter of the bla HMB-1 gene was located 23 bp upstream of the ATG triplet and exhibited the #35 box TCGACA and the #10 box AAATTA with a 17 bp spacing sequence.
A comparison of the genetic environment of bla HMB-1 and bla KHM-1 was difficult, as little is known on the surroundings of the bla KHM-1 gene from the Japanese C. freundii isolate. In the vicinity of bla KHM-1 a 360 bp ORF that encodes the hypothetical protein VP1798 of Vibrio parahaemolyticus was described in the original publication.
14 This ORF was not identified in the genetic environment of bla HMB-1 , so a more comprehensive comparison of the genetic environment was not possible. However, as HMB-1 and KHM-1 show distinct differences from each other and with respect Pfennigwerth et al.
to the large geographical distance between the two isolates, it can be speculated that HMB-1 did not originate from the Japanese KHM-1 and rather represents a de novo mobilization from an unknown environmental source. The GC content of 43% furthermore indicates that both HMB-and KHM-type genes were mobilized into C. freundii and P. aeruginosa, which usually have higher GC contents, of 51% and 66%, respectively. Unfortunately, the origin of almost all subclass B1 MBLs is still unknown and only speculation is possible on potential origins of the bla HMB-1 and bla KHM-1 genes. 29 
MLST analysis
MLST analysis with WGS data showed that the isolate expressed ST395. This is remarkable, as ST395 has only rarely been described in the context of b-lactam resistance in clinical isolates. There are reports from France and Hungary, but ST395 has not been reported as a carrier of carbapenemases in these cases. [30] [31] [32] [33] Cloning and heterologous expression of bla HMB-1
The HMB-1-producing strain showed generally increased MICs of b-lactams, with very high MIC increases for several substrates ( Table 1 ). The highest increases were detected for cephalosporins. MICs of carbapenems were 1 mg/L for imipenem, 2 mg/L for meropenem, 4 mg/L for doripenem and 0.25 mg/L for ertapenem, corresponding to 8-, 64-, 128-and 4-fold increases compared with the control strain, respectively. Similar results were obtained for the KHM-1-producing strain; however, it showed a lower MIC increase for imipenem. As expected, production of HMB-1 had no effect on the MIC of aztreonam.
Enzyme kinetics
The biochemical characterization of HMB-1 showed that the enzyme was capable of hydrolysing all tested b-lactam substrates except aztreonam. The highest hydrolysis rates were detected for cefoxitin, imipenem and ceftazidime (Table 2 ). Both meropenem and ertapenem were hydrolysed with the same efficiency. As expected, HMB-1 was not able to hydrolyse aztreonam. Compared with KHM-1, HMB-1 showed markedly higher turnover numbers for penicillin G and ampicillin, but due to a much lower affinity the hydrolytic efficiency was not significantly different. Both HMB-1 and KHM-1 were able to hydrolyse piperacillin, but with extremely low substrate affinities, resulting in very low hydrolytic efficiencies. This might be an indicator that this antibiotic could still be a therapeutic option against isolates with no additional piperacillin resistance mechanisms.
Regarding cephalosporins, both enzymes were able to hydrolyse cefoxitin and ceftazidime, with similar k cat and K m values, resulting in similar hydrolysis rates. For cefotaxime, HMB-1 showed significantly decreased activity, as the turnover number was 8-fold lower than for KHM-1. HMB-1 and KHM-1 showed distinct differences in carbapenem hydrolysis, with almost 2-fold higher imipenem hydrolysis by HMB-1, while the hydrolytic efficiencies for meropenem and ertapenem were very similar for both enzymes. Characterization of HMB-1
JAC
Overall, the kinetic data were in good agreement with the data obtained from the MIC analyses, with high hydrolysis rates corresponding to high MIC increases. The differences in the kinetic parameters between HMB-1 and KHM-1 were also reflected in the MIC data, e.g. with a higher imipenem MIC for the HMB-1-producing strain, corresponding to a higher hydrolysis rate than measured for KHM-1.
As no information was available in the literature regarding the structure or specific amino acids of KHM-1, and as this enzyme shows an identity of only 74.3% to HMB-1, it was difficult to form a hypothesis on the influence of the differences between the two enzymes on b-lactam hydrolysis without additional structural data. Potentially, the two neighbouring aspartic acid residues of the second zinc-binding site at positions 100 and 101 could lead to disturbances in zinc coordination as T100 plays an essential role in this, 34 but this has to be clarified in future experiments.
Conclusions
In summary, we have identified and characterized a novel chromosomally encoded MBL, HMB-1, in a clinical P. aeruginosa isolate that shows altered characteristics compared with the next nearest relative, KHM-1. This further emphasizes the ongoing diversification of subclass B1 MBLs and the continuing worldwide spread of these enzymes in Gram-negative species of clinical importance.
